国产成人mv免费视频_无码精品毛片波多野吉衣_在线毛片äV网站免费观看_成人亚洲av电影_亚洲爆乳成av人在线网站_中国熟妇乱子hdsex粗_国产无遮挡污在线观看免费Aⅴ_日韩经典精品无码一区18_欧美巨大另类极品ⅴideosbest_午夜成人免费看在线观看
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(華堂寧?)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
中
中
中
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(華堂寧?)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
Our Science
>
Our Science
>
Peer Reviewed Publications
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Peer Reviewed Publications
Diabetes, Obesity and Metabolism
Diabetes remission in drug-na?ve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study
Read More
Diabetes Therapy
Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels
Read More
Nature Communications
2023 March, Nature Communications: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
Read More
Diabetes
Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes
Read More
Nature Medicine
2022 May, Nature Medicine Comments: A new class of drug in the diabetes toolbox.
Read More
Nature Medicine
2022 May, Nature Medicine: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Read More
Nature Medicine
2022 May, Nature Medicine: Dorzagliatin in drug-na?ve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Read More
Clinical and Translational Science
2021 August, Clinical and Translational Science: Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.
Read More
Global Journal of Obesity, Diabetes and Metabolic Syndrome
2020 June / Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China
Read More
Diabetes, Obesity and Metabolism
2018 February / Diabetes, Obesity and Metabolism: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection
Read More
Clinical Pharmacokinetics
2018 April / Clinical Pharmacokinetics: Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics
Read More
Lancet Diabetes Endocrinology
2018 MAY / Lancet Diabetes Endocrinology: New hope for glucokinase activators in type 2 diabetes?
Read More
Lancet Diabetes Endocrinology
2018 May / Lancet Diabetes Endocrinology: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
Read More
Journal of Diabetes Research
2017 January / Journal of Diabetes Research: Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus
Read More
藥學(xué)進(jìn)展
2016年第3期《藥學(xué)進(jìn)展》:葡萄糖激酶激活劑研究進(jìn)展
Read More
藥學(xué)進(jìn)展
2016年第3期《藥學(xué)進(jìn)展》:21世紀(jì)2型糖尿病新藥研發(fā)策略:明鑒病理因素,改善機(jī)體功能
Read More
Drug Design, Development and Therapy
2016 May / Drug Design, Development and Therapy: Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
Read More
Intractable & Rare Diseases Research
2016 October / Intractable & Rare Diseases Research: Orphan drug development in China ? Turning challenges into opportunities
Read More
Clinical Pharmacokinetics
2016 December / Clinical Pharmacokinetics: Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process
Read More
Intractable & Rare Diseases Research
2015 / Intractable & Rare Diseases Research:Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities
Read More
About Us
Company Overview
Company History
Leadership Team
Portfolio Advisory Board
Senior Scientific Advisory Board
Partner
Media center
Research & Development
Inovation
Pipeline
Dorzagliatin
mGluR5
Company Publications
Peer Reviewed Publications
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Media
Company News
Media Releases
Video
Careers
Culture
Join Us
Product
HuaTangNing(華堂寧?)
Subscribe Email
Focus Us
Copyright ? 2024 Hua Medicine (Shanghai) Co., Ltd. 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號(hào): (滬)-非經(jīng)營-2022-0079
滬ICP備14036654號(hào)-1
滬公網(wǎng)安備 31011502013809號(hào)
Privacy Statement
Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our
privacy statement
.
Accept
x